Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).

被引：5
|
作者：
Beltran, Himisha
Dowlati, Afshin
Jain, Prantesh
Johnson, Melissa Lynne
Sanborn, Rachel E.
Thompson, Jonathan Robert
Mamdani, Hirva
Schenk, Erin L.
Aggarwal, Rahul Raj
Sankar, Kamya
Gramza, Ann W.
Anand, Banmeet S.
Choudhury, Noura J.
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] Case Western Reserve Univ, Univ Hosp Siedman Canc Ctr, Cleveland, OH USA
[3] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Earle A Chiles Res Inst, Portland, OR USA
[6] Froedtert, Milwaukee, WI USA
[7] Med Coll Wisconsin, Workforce Hlth, Milwaukee, WI USA
[8] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[9] Univ Colorado Anschutz Med Campus, Aurora, CO USA
[10] Univ Calif San Francisco, San Francisco, CA USA
[11] Cedars Sinai Med Ctr, Los Angeles, CA USA
[12] Harpoon Therapeut Inc, South San Francisco, CA USA
[13] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
261-492-199-2823-7422-11198; 283-197-6219; 613-225-2577-2545; 283-183-138-226; 261-492-199-2823; 613-615-646-4685-2424; 613-225-2782; 6; 4; 3; 38092-34755; 38092-21757; 38092-21759; 5; 2; 1;
D O I：
10.1200/JCO.2024.42.4_suppl.121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：121 / 121
页数：1
相关论文
共 36 条
  • [31] Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC)
    Dowlati, A.
    Byers, L. A.
    Johnson, M. L.
    Aljumaily, R.
    Prenen, H.
    Zhang, A.
    Minocha, M.
    Shetty, A.
    Sadraei, N. Hashemi
    ANNALS OF ONCOLOGY, 2021, 32 : S1172 - S1173
  • [32] Pharmacokinetics of Tarlatamab, a Delta-Like Ligand-3 (DLL3) Targeted Half-Life Extended Bispecific T-Cell Engager (BiTE®) Immunotherapy in Adult Patients with Previously Treated Small-Cell Lung Cancer: Results from DeLLphi-300, a Phase I Multiple-Dose-Escalation Study
    Minocha, Mukul
    Thompson, Corbin G.
    Murphy, Alexis
    Zhou, Yanchen
    Brandl, Christian
    Parkes, Amanda
    Chen, Xi
    Yu, Brian
    Martinez, Pablo
    Houk, Brett E.
    CLINICAL PHARMACOKINETICS, 2024, 63 (12) : 1757 - 1768
  • [33] Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
    Subklewe, Marion y
    Stein, Anthony
    Walter, Roland B.
    Bhatia, Ravi
    Wei, Andrew H.
    Ritchie, David
    Bucklein, Veit
    Vachhani, Pankit
    Dai, Tian
    Hindoyan, Antreas
    Agarwal, Suresh
    Anderson, Abraham
    Khaldoyanidi, Sophia
    Ravandi, Farhad
    BLOOD, 2019, 134
  • [34] Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) plus ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
    Mazieres, J.
    Duruisseaux, M.
    Curcio, H.
    Morizane, C.
    Galot, R.
    Rottey, S.
    Stratmann, J. A.
    Ma, Y.
    Bouzaggou, M.
    Geng, L.
    Wermke, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1076 - S1077
  • [35] Individualized APC targeting VB10.NEO cancer vaccines induce broad neoepitope-specific CD8 T cell responses in patients with advanced or metastatic solid tumors: interim results from a phase 1/2a trial
    Krauss, Jurgen
    Krakhardt, Angela
    Eisenmann, Stephan
    Ochsenreither, Sebastian
    Berg, Kaja C. G.
    Kushekhar, Kushi
    Fallang, Lars-Egil
    Pedersen, Mikkel W.
    Torhaug, Siri
    Slot, Karsten B.
    Schjetne, Karoline
    CANCER RESEARCH, 2023, 83 (08)
  • [36] Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B- Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study
    Bar, Noffar
    Victoria Mateos, Maria
    Ribas, Paz
    Hansson, Markus
    Paris, Laura
    Hofmeister, Craig C.
    Rodriguez Otero, Paula
    Aranzazu Bermudez, Maria
    Martin, Thomas
    Santoro, Armando
    Yee, Andrew J.
    Creignou, Maria
    Encinas Rodriguez, Cristina
    Cerchione, Claudio
    De La Rubia, Javier
    Oriol, Albert
    Waibel, Heidi
    Besemer, Britta
    Thompson, Ethan
    Kiesel, Brian
    Chen, Jinjie
    Chung, Alexander
    Boss, Isaac W.
    Gaudy, Allison
    Li, Shaoyi
    Hsu, Kevin
    Godwin, Colin
    Burgess, Michael R.
    San-Miguel, Jesus
    Costa, Luciano
    BLOOD, 2023, 142
1234